Eli Lil­ly’s M&A Fri­day; No­var­tis' TIG­IT breakup; One big hire and one big ex­it; Re­verse merg­er, shut­down and white flags; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

We’re just a few days away from un­veil­ing this year’s list of women blaz­ing tri­als in bio­phar­ma R&D. In ad­di­tion to an award cer­e­mo­ny in which you will get to hear snip­pets from our in­ter­view with hon­orees. I will be host­ing Fiona Mar­shall, pres­i­dent of the No­var­tis In­sti­tutes for Bio­Med­ical Re­search, for a fire­side chat, while my col­league Nicole De­Feud­is will mod­er­ate a pan­el with a trio of women lead­ers who are mak­ing their voic­es heard. We hope to see you there.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER